Cross-Portfolio Strategy
Accelerating immunotherapy development – building a fast-to-market strategy.
Driven by an internal perception of a convoluted approach to clinical development, our client sought to dissect the case history of four high profile products/companies that demonstrated disproportionately speedy regulatory approval timelines.
Eradigm’s detailed appraisal of this complex scope provided extensive learnings, enabling our client to drive multiple cross-functional workstreams to rethink their approach to more dynamic decision making during development.
Share this post
![Testimonial about Cross-Portfolio Strategy 1 Testimonial about Cross-Portfolio Strategy 1](https://eradigm.com/wp-content/uploads/2019/04/CaseStudy_Cross-Portfolio-Strategy_1.jpeg)